Pharm
Bivalirudin
search
Bivalirudin
, Angiomax, Hirulog
See Also
Direct Thrombin Inhibitor
Dabigatran
(
Pradaxa
)
Argatroban
Desirudin
Indications
Patients at risk for
Heparin Induced Thrombocytopenia
Percutaneous Coronary Intervention
(PCI)
Unstable Angina
or
NSTEMI
while awaiting PCI (off label)
Mechanism
Hirudin
Direct Thrombin Inhibitor
Bivalent peptide derivatives from
Salivary Gland
of medicinal leaches
Dosing
Coadminister with
Aspirin
325 mg orally daily
Percutaneous Coronary Intervention
(PCI) for patients at risk for HIT
Bolus: 0.75 mg/kg IV prior to PCI
Next: 1.75 mg/kg/hour until PCI completed and for up to 4 hours after PCI
Decrease to 1 mg/kg/hour if
Creatinine Clearance
<30 ml/min
Decreased to 0.23 mg/kg/hour if on
Hemodialysis
Maintenance: 0.2 mg/kg/hour for up to 20 hours
Unstable Angina
or
NSTEMI
while awaiting PCI (off label)
Coadminister with
Dual Antiplatelet Therapy
(e.g.
Aspirin
and
Ticagrelor
)
May be used with
Glycoprotein IIB/IIIA Inhibitor
Bolus: 0.1 mg/kg IV
Maintenance: 0.25 mg/kg/hour until PCI
Safety
Pregnancy Category B
Unknown safety in
Lactation
Adverse Effects
Major Bleeding
Allergic Reaction
Serious
Allergic Reaction
s including
Anaphylaxis
may occur with
Hirudin
s
Highest risk on
Hirudin
re-exposure or in GFR <30 ml/min
Drug Interactions
Warfarin
INR levels are inaccurate while on Bivalirudin
Monitor
Warfarin
coagulation with
Activated Clotting Time
(ACT)
Resources
Bivalirudin (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af943fa0-ab0f-4b62-9ff0-54ee24cdb772
References
Hamilton (2020) Tarascon Pocket Pharmacopoeia
Berlioz (2023) Bivalirudin, StatPearls, Treasure Island, FL
https://www.ncbi.nlm.nih.gov/books/NBK557823/
Type your search phrase here